Figure 1 Mechanism of action of caplacizumab

Slides:

Advertisements

Similar presentations

HYSTORY: The Registry was established in AIM OF THE REGISTRY: - understanding the pathogenesis of HUS/TTP - studying the genetic and biochemical.

Advertisements

Coagulation: Review & Lab techniques

Hemorrhagic diseases. Lesions of the blood vessels Lesions of the blood vessels Abnormal platelets Abnormal platelets Abnormalities in the coagulation.

Hemostasis & Thrombosis: Platelet Disorders Beth A. Bouchard BIOC 212: Biochemistry of Human Disease Spring 2005.

HEMOSTASIS Hemostasis

Biomedical R&D Folie (slide) 1 Saratin - mechanism of action vWF Platelet.

Basic Science Review A Tale of Three Proteins by Jack B. Alperin, MD, FACP.

THROMBOTIC THROMBOCYTOPENIC PURPURA Emily O. Jenkins MD AM Report

BCSLS Hematology Telehealth Broadcast

Lower levels of ADAMTS13 are associated with cardiovascular disease by Supakanya Lasom Master Degree Student of Medical Sciences, Bongers T.N, Bruijne.

HEMOSTASIS Primary hemostasis.

Thrombotic Thrombocytopenic Purpura(TTP) Post -AllogeneicTransplant A haematological emergency: a nursing.

HIV-Associated Thrombotic Microangiopathy

Bleeding and Kristine Krafts, M.D. Thrombotic Disorders.

Von Willebrand Disease

Coagulation tests CBC- complete blood count

Venous Thromboembolism-1

Congenital bleeding disorders

HAEMOSTASIS AND THROMBOSIS Regulation of coagulation

Activation of the Hemostatic System During Cardiopulmonary Bypass

Bleeding disorders Dr. Feras FARARJEH.

Platelets disorders.

Figure 6 Effects of adiponectin on podocyte function

Figure 1 Pre-eclampsia prevents VEGF signalling in endothelial cells

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 1 Pulmonary oedema in AKI

Nat. Rev. Nephrol. doi: /nrneph

“Radical” model of thrombosis

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow by.

Figure 1 Mechanism of thrombus formation during ST-segment

Congenital bleeding disorders

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura by Evaren E. Page, Johanna A. Kremer.

Nat. Rev. Nephrol. doi: /nrneph

Volume 55, Issue 6, Pages (December 2011)

Figure 4 Tumour-induced neutrophil extracellular trap

The Fascinating World of Haemostasis and Thrombosis

Figure 1 Innate immune responses in atherosclerosis

Bleeding and Thrombotic Disorders Kristine Krafts, M.D.

Blocking VWF platelet binding to treat TTP

Figure 2 Prevention of antigen–antibody

by J. Evan Sadler Blood Volume 112(1):11-18 July 1, 2008

Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent.

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Inherited disorders of platelet function

Nat. Rev. Nephrol. doi: /nrneph

Bleeding disorders Dr. Feras FARARJEH.

Figure 3 Cascade of events leading from AKI to ALI

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Mechanosensing: A Regulation Sensation

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic.

Figure 1 Structure of ADAMTS13

Figure 1 Mechanisms of platelet adhesion and aggregation

Patients With Severe Aortic Valve Stenosis and Impaired Platelet Function Benefit From Preoperative Desmopressin Infusion Barbara Steinlechner, MD, Petra.

The Role of Endothelial Cell Injury in Thrombotic Microangiopathy

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Platelet receptors and available pharmaceutical options

Figure 3 Pathophysiological events and preventive

The molecular biology of thrombotic microangiopathy

Figure 3 Preventive strategies for CSA-AKI

Nat. Rev. Cardiol. doi: /nrcardio

Approach to Bleeding Disorders DR

The Immunological Barrier to Xenotransplantation

Figure 2 Protective functions of HDL

The molecular biology of thrombotic microangiopathy

Thrombotic thrombocytopenic purpura

Presentation transcript:

Figure 1 Mechanism of action of caplacizumab Figure 1 | Mechanism of action of caplacizumab. a | In patients with acquired thrombotic thrombocytopenic purpura (TTP), platelets adhere via glycoprotein Ibα to activated A1 domains of ultra-large von Willebrand factor (VWF) multimers that are attached to the endothelial cells and stretched under high fluid shear stress in the microcirculation. Adherent platelets bind circulating ultra-large VWF multimers leading to platelet clumping and the development of microvascular thrombosis. b | Caplacizumab binds to the A1 domains of VWF preventing platelet adhesion and microvascular thrombosis and enabling normalization of the platelet count. Lämmle, B. (2016) Caplacizumab accelerates resolution of acute acquired TTP Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.47